Fundraising Fox
Ovidrx
NASDAQ: OVIDNew York, US · Founded 2014 · 43 employees on LinkedIn · 2 known investors
Find your way into Ovidrx
1,010 people in our graph share verified history with the Ovidrx team — schools, employers, funds. One of them is your warm intro.
Shwen Gweeunlockedknows Victoria Fort · together at inVentiv Health Public Relations Group (overlapped)
knows the team · via Frontier Medicines
×2knows the team · via Affinia Therapeutics
knows the team · via Syneos Health
×2knows the team · via Burson-Marsteller
×3knows the team · via Columbia University Irving Medical Center
Ovid Therapeutics develops medicines for children and adults with epilepsies and brain conditions, focusing on anti-seizure and neurological treatments. The company is led by a team with decades of combined experience in biotech and pharmaceutical development, having supported the launch of more than 25 new medicines.
Founders & leadership
Ovidrx was founded in 2014 by Matthew J. During and Jeremy M. Levin.
MA
Meg AlexanderPresident & Chief Executive OfficerMeg Alexander is President and Chief Executive Officer of Ovid Therapeutics, which develops anti-seizure and neurological treatments for pediatric and adult patients. She previously spent over two decades in biopharmaceutical and pharmaceutical roles at companies including Pfizer, Novartis, Amgen, Janssen, and Boehringer Ingelheim, and founded the Reputation and Risk Management business at Syneos Health.
CC
Charles CarterChief Financial OfficerHe has 25 years of financial management experience across biotech, pharmaceuticals, and other regulated industries, with expertise in accounting, strategic planning, business development, and regulatory compliance.
VF
Victoria FortChief Strategy OfficerChief Strategy Officer of Ovidrx, a biotech company developing medicines for epilepsies and brain conditions; brings experience in pharmaceutical and biotech development.
PK
Petra KaufmannChief Medical OfficerPetra Kaufmann is Chief Medical Officer at Ovid Therapeutics, which develops anti-seizure and neurological medicines. She is a neurologist and physician-scientist with expertise in drug development across IND, clinical trial, and regulatory stages, as well as gene therapy, and previously led large collaborative research programs including NeuroNEXT.
MM
Manal MorsyChief Regulatory OfficerManal Morsy has more than 30 years of experience in medical and scientific roles, including nearly 30 years in pharmaceutical and biotech development across biologics, vaccines, and small molecules. She has led global regulatory affairs functions for multiple organizations and has supported regulatory submissions and approvals for treatments across epilepsy, neurological disorders, vaccines, and rare diseases.
KN
Kevin NorrettChief Business OfficerKevin Norrett is Chief Business Officer at Ovid Therapeutics, which develops anti-seizure and neurological medicines. Previously, he held a strategy and portfolio leadership role at Soleno Therapeutics, where he contributed to work that preceded Soleno's acquisition by Neurocrine Biosciences for $2.9 billion.
Board
MF
Mark FeldbergBoard director
ES
Eliseo SalinasSenior R&D Advisor
Investors · 2
Sanofi Ventureslisted by Sanofi VenturesCambridge · $5M
How we know: Sanofi Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Funding
SEC filings, press & company announcements$105.9M disclosed across 3 of 6 rounds · 1900–2026
- Undisclosed amountPIPE financingMar 2026Source ↗
▶$25.9MraisedJan 2017 · 1 investors · Other Health CareRule 506(b)
▶$25.9MraisedJan 2017 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Amit RakhitExecutive Officer
- Bart FriedmanDirector
- Yaron WerberExecutive Officer
- Jeremy M. LevinExecutive Officer, Director
- Douglas E. WilliamsDirector
- Karen BernsteinDirector
- Matthew J. DuringExecutive Officer, Director
- Offering amount
- $25.9M
- Amount sold
- $25.9M
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$75MraisedAug 2015 · 50 investors · Other Health CareRule 506(b)
▶$75MraisedAug 2015 · 50 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Yaron WerberExecutive Officer
- Matthew J. DuringExecutive Officer, Director
- Jeremy M. LevinExecutive Officer, Director
- Offering amount
- $75M
- Amount sold
- $75M
- Sales commissions
- $4M
- Placement agents
- Cowen and Company, LLC
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$5.1MraisedMar 2015 · 5 investors · Other TechnologyRule 506(b)
▶$5.1MraisedMar 2015 · 5 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Jeremy M. LevinExecutive Officer, Director
- Matthew J. DuringExecutive Officer, Director
- Mark FeldbergDirector
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$369Mvaluation at IPOMay 2017 · $15.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Ovidrx do?
- Ovid Therapeutics develops medicines for children and adults with epilepsies and brain conditions, focusing on anti-seizure and neurological treatments. The company is led by a team with decades of combined experience in biotech and pharmaceutical development, having supported the launch of more than 25 new medicines.
- Who founded Ovidrx?
- Ovidrx was founded by Matthew J. During, Jeremy M. Levin in 2014.
- Who are Ovidrx's investors?
- Ovidrx's investors include BioBrit, Sanofi Ventures.
- How much funding has Ovidrx raised?
- Ovidrx has disclosed $105.9M raised across 3 of its 6 known rounds.
- Where is Ovidrx headquartered?
- Ovidrx is headquartered in New York, US.